Analysis of the RIMDAMAL trial

Affiliations

¹ MRC Tropical Epidemiology Group, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK. Electronic address: john.bradley@lshtm.ac.uk.
² Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
³ MRC Tropical Epidemiology Group, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.

Comment

John Bradley et al. Lancet. 2019.

. 2019 Sep 21;394(10203):1005-1006.

doi: 10.1016/S0140-6736(19)31663-0. Epub 2019 Jul 16.

¹ MRC Tropical Epidemiology Group, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK. Electronic address: john.bradley@lshtm.ac.uk.
² Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
³ MRC Tropical Epidemiology Group, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.

No abstract available

Comment on

Efficacy and risk of harms of repeat ivermectin mass drug administrations for control of malaria (RIMDAMAL): a cluster-randomised trial.
Foy BD, Alout H, Seaman JA, Rao S, Magalhaes T, Wade M, Parikh S, Soma DD, Sagna AB, Fournet F, Slater HC, Bougma R, Drabo F, Diabaté A, Coulidiaty AGV, Rouamba N, Dabiré RK. Foy BD, et al. Lancet. 2019 Apr 13;393(10180):1517-1526. doi: 10.1016/S0140-6736(18)32321-3. Epub 2019 Mar 14. Lancet. 2019. PMID: 30878222 Free PMC article. Clinical Trial.